Viprinex

Viprinex™

Ancrod, formerly Arvin™ Critical care An orphan drug from Malayan pit viper venom, used in Pts with acute ischemic stroke to anticoagulate heparin-intolerant Pts undergoing CABG. See CABG.
References in periodicals archive ?
Obvious examples include insulin, which in its earliest, nonsynthetic form was manufactured from the pancreatic enzymes of pigs and calves, Primarin, an estrogen derived from pregnant mare's urine, and the anticoagulant Viprinex, which uses the venom of the Malaysian pit viper.
Beastly physic
Viprinex is a defibrinogenating agent derived from the venom of the Malayan pit viper.
Presentations at 2007 European Stroke Congress Highlights New Direction for Viprinex(TM) (ancrod)
today announced the completion of a snake facility in Moorrege, Germany, that will provide the venom used to produce Viprinex, which NTI is currently studying as a potential treatment for acute ischemic stroke.
Neurobiological Technologies Inc. Completes 'Snake' Facility for Venom Used as Stroke Treatment
Baxter will aseptically fill and package the drug product, Viprinex, into its finished form, along with the corresponding placebo.
NEUROBIOLOGICAL TECHNOLOGIES SIGNS VIPRINEX PACTS
If pivotal Phase III trials for Viprinex are commenced as currently planned, NTI will issue an additional 2,375,176 shares and pay an additional $2 million to the Empire stockholders.
NEUROBIOLOGICAL REPORTS 4TH QTR NET LOSS OF $1,O15,000
Stroke patients currently have few treatment options, and Viprinex is designed to expand the treatment window from three hours to six hours.
Dutton Associates Announces Investment Opinion: Neurobiological Technologies Strong Speculative Buy Rating Maintained In Updated Coverage By Dutton Associates
Assuming accrued costs associated with the Viprinex program are fully paid off by June 30, 2009 as currently estimated, the Company expects to end its fiscal year with approximately $23 million in cash, short-term and long-term investments.
Neurobiological Technologies Reports Third Quarter Fiscal 2009 Financial Results
And thirdly, the timetable for entering patients into the Viprinex clinical trials and the subsequent interim analysis has been extended for one quarter.
Dutton Associates Announces Investment Opinion: Neurobiological Technologies Strong Speculative Buy Rating Maintained In Updated Coverage By Dutton Associates
Although partial funding for the Viprinex program was achieved through the sale of rights and assets of Xerecept[R], and by an increasing stream of royalties related to sales of memantine, it was necessary to raise substantial additional funds externally through the sale of equity.
Dutton Associates Announces Investment Opinion: Neurobiological Technologies Strong Speculative Buy Rating Maintained in Updated Coverage by Dutton Associates
In an effort to maximize the potential of the Viprinex program, the Company appointed Warren W.
Dutton Associates Announces Investment Opinion: Neurobiological Technologies Strong Speculative Buy Rating Maintained In Updated Coverage By Dutton Associates
However, we want to emphasize that we believe the relative success or failure of an investment in NTI rests on the results of the Viprinex trials with some protection on the downside being afforded by the growing royalty revenue from Memantine.
Dutton Associates Announces Investment Opinion: Neurobiological Technologies Strong Speculative Buy Rating Maintained in Updated Coverage by Dutton Associates
We also believe that if Viprinex is successful, a market capitalization for NTI in the $0.
Dutton Associates Announces Investment Opinion: Neurobiological Technologies Strong Speculative Buy Rating Maintained In Updated Coverage By Dutton Associates
Medical browser ?
Full browser ?